BASE10 Genetics, DNA Link announced their collaboration on a research project to evaluate the usability of DNA Link's AccuFind COVID-19 IgG antibody test in a healthcare setting.
At present, most antibody tests on the market require samples to be sent to a lab for analysis. The extra cost and time associated has constrained population wide studies of SARS-CoV-2 antibodies.
"An antibody test that can be done at the point of care without the need for a lab can more quickly provide information clinicians and administrators need to make decisions for their nursing home patients and staff," said Dr. Michael Fang, BASE10 CEO.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
"This research is an important milestone in our efforts to expand access to antibody testing," said Elizabeth Freund, VP of Innovation at BASE10. "DNA Link's AccuFind performs very well in laboratory settings. The next logical step is to test its performance when used by healthcare professionals outside the lab. Many factors have the potential to affect test performance in lesser controlled settings so it's an ambitious goal to be sure. However, if FDA believes the data demonstrates its safety and effectiveness under these conditions, we'll be one step closer to FDA emergency use authorization for point of care use."